New Haven, Conn., and Philadelphia — Virscio, a transformational translational research organization, today announced the deployment of Proscia®'s Concentriq for Research to accelerate the company’s therapeutic breakthroughs and help improve the efficiency of its drug development research
Utilizing Proscia’s digital pathology platform to unify its global team of scientists and streamline research and development, the adoption of Concentriq for Research will allow Virscio to provide sponsors with more accurate and more complete preclinical development insights and help them get life-saving therapeutics to patients sooner.
Virscio was established to help its partners accelerate therapeutic advances for ophthalmology, central nervous system, cardiovascular, and metabolic-related diseases and disorders by studying the most clinically relevant in vivo test systems. As pathology plays a key role in these studies, Virscio implemented Concentriq for Research to centralize its global pathology operations and help its scientists to predict human response with improved accuracy.
A leader in digital and computational pathology solutions, Proscia’s Concentriq for Research is a cloud-based image and data management platform that unifies pathology operations and accelerates routine workflows across the connected enterprise, Concentriq for Research allows Virscio to store and organize its pathology data, providing intuitive, secure, and fast access to its distributed team.
Concentriq for Research also streamlines collaboration among Virscio’s scientists, sponsors, and external collaborators with live, asynchronous, and remote image viewing. The platform additionally offers Virscio and its clients with best-of-breed interoperability, integrating with leading scanners, image analysis solutions, and artificial intelligence (AI) applications, and will continue to sit at the center of Virscio’s pathology operations as the organization’s needs evolve.
“Translating concept to clinical success requires innovative technology, and we’ve found this in Concentriq for Research,” said Matthew Lawrence, M.D., Ph.D., Virscio’s Chief Executive Officer and Chief Scientific Officer. “We chose the platform as the first component of our digital pathology ecosystem because it plays a critical role in empowering our team to make the most of our data.”
Virscio and other life sciences organizations have been on the forefront of digital pathology adoption, generating millions of images and increasingly complex data to better inform their research. The company’s early adoption of digital pathology shifts the standard from microscope to whole-slide image and enables Virscio’s scientists to improve productivity, see quality gains in routine workflows, and unlock new clinically impactful insights informed by AI.
With lengthening timelines and increasing drug development costs— the average drug can take 10 to 15 years to develop, and cost more than $2.6 billion to bring to market — the selection of Proscia’s digital pathology platform allows Virscio to provide sponsors overcome lengthy timelines and reduce these development costs through their innovative and transformational approach to drug research.
“We are excited to welcome Virscio to the growing roster of organizations turning to Concentriq for Research to accelerate therapeutic innovation,” David West, Proscia’s Chief Executive Officer, said. “Virscio is pioneering a new wave of translational research, and we look forward to seeing the impact of digital pathology in helping to overcome the critical challenge of R&D efficiency.”
About Proscia: Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 10 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.
About Virscio: Virscio is a specialty translational research organization developing and providing innovative preclinical and translational research services, in vivo nonhuman primate disease modeling, and related preclinical and histopathology services to meet the preclinical, translational, and regulatory research needs of the life sciences, biotechnology, and pharmaceutical industries. Virscio specializes in non-GLP and GLP in vivo study design, execution, and sample, data, and image analysis to enable rapid translation of preclinical therapeutic candidates from early proof of concept to IND-enabling studies, leveraging unique and significant access to nonhuman primates and integrated therapeutic domain expertise and capabilities.
For more information, please visit www.virscio.com.
For media inquiries, please contact:
Christopher Stanley
Chief Business Officer